Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Certificate of Incorporation of the Company, Effective on May 14, 2019
- 3.2 Amended and Restated Certificate of Incorporation of the Company, Effective on May 15, 2019
- 3.3 Bylaws of the Company, Effective As of May 15, 2019
- 10.1 Amended and Restated Registration Rights Agreement Dated May 15, 2019
- 10.4 Escrow Agreement Dated May 13, 2019
- 10.7 Indemnification Agreement
- 14.1 Insider Trading Policy
- 17.1 Resignation of Peixin Xu
- 21.1 Subsidiaries of Registrant
- 99.1 Audited Financial Statements of Xynomic Pharmaceuticals, Inc.
- 99.2 Pro Forma Financial Statements
- 99.3 Press Release Dated May 15, 2019
XYNPW similar filings
Filing view
External links
Exhibit 17.1
RESIGNATION
I, Peixin Xu, hereby resign as Director and Chairman of the Board, President and any other office that I hold in Bison Capital Acquisition Corp., a Delaware corporation (the “Company”), effective upon the consummation of the transactions contemplated by certain Agreement and Plan of Merger, dated as of September 12, 2018, as amended, by and among the Company, Bison Capital Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Bison, Xynomic Pharmaceuticals, Inc., a Delaware corporation (“Xynomic”), and Yinglin Mark Xu, an individual residing in Shanghai, China, solely in his capacity as the Shareholder Representative of Xynomic.
Date: May 14, 2019 | /s/ Peixin Xu |
Name: Peixin Xu |